The efficacy and role of pemigatinib

Pemigatinib (Pemigatinib) is a selective, potent, orally competitive inhibitor of FGFR1, FGFR2, and FGFR3. Clinical studies evaluated the safety and antitumor activity of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma (with or without FGF/FGFR alterations).

In patients with FGFR2 fusion or rearrangement, the anti-tumor activity of pemetinib is superior to other second-line chemotherapy and targeted therapy reports13 (the proportion of patients with objective response was 9.5%, and the proportion of patients with no progression was The survival time was 2.6 months and the overall survival was 6.5 months. In a major study involving 108 patients with biliary tract cancer with abnormal FGFR2, Pemi. Pemetinib was effective in reducing the size of cancer lesions in approximately 37% of patients whose cancers shrank for an average of eight months. Pemetinib increased serum phosphate as a result of FGFR inhibition. Levels. Serum phosphate increased with increasing exposure over the dose range of 1 to 20 mg once daily (0.07 to 1.5 times the recommended dose), and the risk of hyperphosphatemia increased with higher pemetinib exposure.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.